Core Viewpoint - The announcement indicates that China National Pharmaceutical Group Modern (国药现代) has received approval for the active pharmaceutical ingredient (API) phosphoric acid sitagliptin, which is primarily used for improving blood sugar control in patients with type 2 diabetes [1] Group 1: Company Developments - The company's wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd. (国药威奇达), has received the "Approval Notice for Chemical Raw Material Drug Listing Application" from the National Medical Products Administration [1] - The approval signifies that the phosphoric acid sitagliptin API meets the regulatory requirements for drug registration in China, allowing it to be marketed domestically [1] - This development will further enrich the company's specialized API product portfolio [1]

Core Viewpoint - Gannee Pharmaceutical's stock price increased by 1.05% to 64.36 yuan as of August 6, 2025, with a notable intraday rebound and a peak of 65.90 yuan [1] Company Overview - Gannee Pharmaceutical specializes in the biopharmaceutical sector, focusing on the research, production, and sales of diabetes treatment drugs, including insulin analogs and human insulin [1] Market Performance - The trading volume on August 6 reached 1.322 billion yuan, with a turnover rate of 3.65% [1] - The net inflow of main funds on August 6 was 69.8268 million yuan, with a cumulative net inflow of 153 million yuan over the past five days [1] - The current total market capitalization of the company is 38.685 billion yuan, while the circulating market value stands at 36.132 billion yuan [1]